than Friday the school late call would on when that everybody, aged you afternoon. and have Halloween it for thank rather on you, be calling be you, Jim, of better Friday, trick-or-treating. We some Thank the in, would to thought children on with
taking we So, time this you update. to hear appreciate
development are we which fever to Hemopurifier the Breakthrough class FDA and of The proprietary that’s Device circulating in individuals the a second the late in types device standard therapeutic viruses, single and XXXX, treatment of glycosylated designation virtually shown of Hemopurifier, the the all in therapy, of viruses including that for device, is breakthrough affect to cancer for hemorrhagic unresponsive a the first promoting which the participate the with and been cancer, care of designed received use the Aethlon, designated are Ebola, At treatment and our was And continuing depletion then, develop other disease. to by for the metastatic intolerant in Hemopurifier or have severity humans. who viruses of viruses, with either exosomes previously cancer advanced or exosomes.
Hemopurifier in by FDA, divisions the treatment multiple the actually designations the two we separate were Device So, different potential Breakthrough diseases. at that of different the recognizing granted for have
safety Hepatitis eventful Hemopurifier. with patients on quarter. trials a very patients clinical This with number of work advanced in viral strong treatments that and had cancer. XXX initiation the various years a actually follows representing database We in we've for C, Now, of of announced very preparing establishing the Hemopurifier for were viral predominantly in disease, a work metastatic we over infections, previously
and person Head cancer. development discuss of Dr. the FDA Quality who me, newly Chuck including for our team, to met our Fisher, in and our in Lisa joined with Boswell, this year, this us Regulatory, Hemopurifier has with in me, of afternoon program Affairs is June In and Bethesda recruited
Exemption filing. with on or Device days Following was after FDA trials an XX Xth, cancer. initiate October that clinical to approved than meeting in IDE in IDE less September, application Investigational filed That we
final We center Board will at a to the consent to approved have where initiating Institutional trials, to that be medical and on submit document by we're the the to informed Review FDA going conduct informed trial. consent prior
like I'd digressed Breakthrough of and just in for a of couple Now, minute take designation. minutes process the on the context take to comment to our a review Device
been our to anything breakthrough I case. that that designation experience has the a view think there of provide there FDA convince the that but was that quickly fact the generated and they people underlines marketing is is this for companies, were kind a that and something out of somewhat moving by ploy
In September, this early the the we three received feedback situation, we in later. agency days filed and our first from IDE
received we seven and days, filing. XX less subsequent the The we additional then six comments approved XX rounds was days. amendments in the IDE of in During XX days after than mandated filed
Prior over or and on IND the can XX, to of years supports drug days that legislation in my either for would is patiently file in standard was say this Now, and day an FDA wait development, process you call biologics it, designation your XX trial trial. breakthrough that experience would of in and start an start would you the unprecedented. XX or and you the can't or you absolutely IDE your device email you
supports is, best what forth, is was you exactly this of legislation by collegial tell designation. back I breakthrough with it thing type that works. communication the and can And the the So, agency intended interactive the
metastatic the the advanced start in a the neck. cancer We’re patients world, now Feasibility of called and device trial earliest up the in is which clinical it’s head with Early trial of in an process and/or Study,
patients know, can are can very have head definitive and few who disease, or who very is candidates cancer. Even a for generally survival. surgery amenable options quickly, surgically and disease, cancer recur, get patients have second radiation, radiation deadly very neck they and not recur limited or they may you primary do As
in, in least medicine. this So, the progress solid is tumors of made that one the we’ve
Merck Keytruda the immuno-oncology meaningful a who of not is inhibitors, or surgery in disease. that patients known of of with the this was also treatment disease treatment checkpoint the advance initial one Recently, newer present in radiation. pembrolizumab represents to agents, Keytruda approved called amenable from or
unfortunately, majority do add drug; life patients to months, not respond, only to those this expectancy. However, unfortunately respond the their not do who years of and
exact we similar the Hemopurifier. and targeted collaborating Recent that have other are laboratories that work been through for immunosuppressive laboratories resistant one is mechanisms, studies tumor clearance tumors exosomes, with primary and by which from indicated shedding are the the to that Keytruda of of the the particles by drugs
trial With at cancer the exosomes. the a immunosuppressive the it conducted Keytruda will to with decrease This combination number will this we initial investigate of center neck of to major circulating in and head a details is treatment will with mind, our be Hemopurifier trial in have the more trial cancer launched. of and the a United about is when discuss States, preceding
to the should asking comment development that I infections, continue for we pursue before of fever the to Chuck particularly Ebola. viral life-threatening hemorrhagic Hemopurifier briefly say viruses like
treating diseases, will patients targets increase with viral area these We potential investigate in intake solid to transplant in other be organs. -- the also of the opportunistic translated improve
potential the view but clearer So, to more viral path a approval we to the as for we also cancer means, continue field, and Hemopurifier. by being we developed rapid there, no abandon
December Chairman, run Dr. drug me I minute Company Fisher, Chuck common to together a in like imminently We So recruited for and Charles Fisher, device years. development Chuck for program. have to organization. how restructuring. the our philosophy because stop a and last to Chuck many been share the involved about has I’d a management worked development and with about
been different from one, very So, a process. is a our meaningful me a and this trusted Chairman a the for Chuck clear has a and advisor relationship during generally and between part relationship entire CEO,
process been and involved imminently do Chuck the want in you’ve you comments it? on since So, make any to regulatory development
